Being prepared: Bioterrorism and mass prophylaxis: Part i

Advanced Emergency Nursing Journal

Volumn 36, Issue 3, 2014, Pages 226-238

  Weant, Kyle A ^a   Bailey, Abby M ^b   Fleishaker, Elise L ^b   Justice, Stephanie B ^b  

^a NORTH CAROLINA DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Anthrax; Bacillus anthracis; Biological warfare; Bioterrorism; Francisella tularensis; Tularemia; Yersinia pestis

Indexed keywords

BACTERIA; BIOLOGICAL WARFARE; CONTINUING EDUCATION; DISASTER PLANNING; EMERGENCY HEALTH SERVICE; HUMAN; ORGANIZATION AND MANAGEMENT; PATHOGENICITY;

BACTERIA; BIOTERRORISM; DISASTER PLANNING; EDUCATION, CONTINUING; EMERGENCY SERVICE, HOSPITAL; HUMANS;

EID: 84905505453     PISSN: 19314485     EISSN: 19314493     Source Type: Journal    
DOI: 10.1097/TME.0000000000000029     Document Type: Article

References (45)

1. Arnon, S. S., Schechter, R., Inglesby, T. V., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Tonat, K. (2001). Botulinum toxin as a biological weapon: Medical and public health management. The Journal of the American Medical Association, 285(8), 1059-1070.
2. Borio, L., Inglesby, T., Peters, C. J., Schmaljohn, A. L., Hughes, J. M., Jahrling, P. B., Tonat, K. (2002). Hemorrhagic fever viruses as biological weapons: Medical and public health management. The Journal of the American Medical Association, 287(18), 2391-2405.
3. Branda, J. A., & Ruoff, K. (2002). Bioterrorism. Clinical recognition and primary management. American Journal of Clinical Pathology, 117(Suppl.), S116-S123.
4. Breman, J. G., & Arita, I. (1980). The confirmation and maintenance of smallpox eradication. New England Journal of Medicine, 303(22), 1263-1273. doi:10.1056/NEJM198011273032204
5. Breman, J. G., & Henderson, D. A. (1998). Poxvirus dilemmas-monkeypox, smallpox, and biologic terrorism. New England Journal of Medicine, 339(8), 556-559. doi:10.1056/NEJM199808203390811
6. Bush, L. M., Abrams, B. H., Beall, A., & Johnson, C. C. (2001). Index case of fatal inhalational anthrax due to bioterrorism in the United States. New England Journal Medicine, 345(22), 1607-1610.
7. Bush, L. M., & Perez, M. T. (2012). The anthrax attacks 10 years later. Annals of Internal Medicine, 156(1, Pt. 1), 41-44.
8. Centers for Disease Control and Prevention. (1988). Management of patients with suspected viral hemorrhagic fever. Morbidity and Mortality Weekly Report, 37(Suppl. 3), 1-16.
9. Centers for Disease Control and Prevention.,M. T. (2001). Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. Morbidity and Mortality Weekly Report, 50(42), 909-919.
10. Centers for Disease Control and Prevention. (2007). Bioterrorism overview. Retrieved September 18, 2013, from http://www.bt.cdc.gov/bioterrorism/ overview.asp
11. Centers for Disease Control and Prevention. (2012). Strategic national stockpile. Retrieved February 25, 2014, from http://www.cdc.gov/phpr/stockpile/ stockpile.htm
12. Cleri, D. J., Porwancher, R. B., Ricketti, A. J., Ramos-Bonner, L. S., & Vernaleo, J. R. (2006). Smallpox as a bioterrorist weapon: Myth or menace? Infectious Disease Clinics of North America, 20(2), 329-357, ix.
13. Conrad, F. G., LeCocq, F. R., & Krain, R. (1968). A recent epidemic of plague in Vietnam. Archives of Internal Medicine, 122(3), 193-198.
14. Cronquist, S. D. (2004). Tularemia: The disease and the weapon. Dermatologic Clinics, 22(3), 313-320, vi-vii.
15. Darling, R. G., Catlett, C. L., Huebner, K. D., & Jarrett, D. G. (2002). Threats in bioterrorism. I: CDC category A agents. Emergency Medicine Clinics of North America, 20(2), 273-309.
16. Daya, M., & Nakamura, Y. (2005). Pulmonary disease from biological agents: Anthrax, plague, Q fever, and tularemia. Critical Care Clinics, 21(4), 747-763, vii.
17. Dennis, D. T., Inglesby, T. V., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Tonat, K. (2001). Tularemia as a biological weapon: Medical and public health management. The Journal of the American Medical Association, 285(21), 2763-2773.
18. Eliasson, H., Broman, T., Forsman, M., & Back, E. (2006). Tularemia: Current epidemiology and disease management. Infectious Disease Clinics of North America, 20(2), 289-311, ix.
19. Franz, D. R., Jahrling, P. B., Friedlander, A. M., McClain, D. J., Hoover, D. L., Bryne, W. R., Eitzen, E. M. (1997). Clinical recognition and management of patients exposed to biological warfare agents. The Journal of the American Medical Association, 278(5), 399-411.
20. Henderson, D. A. (1999). The looming threat of bioterrorism. Science, 283(5406), 1279-1282.
21. Henderson, D. A., Inglesby, T. V., Bartlett, J. G., Ascher, M. S., Eitzen, E., Jahrling, P. B., Tonat, K. (1999). Smallpox as a biological weapon: Medical and public health management. Working Group on Civilian Biodefense. The Journal of the American Medical Association, 281(22), 2127-2137.
22. Hendricks, K. A., Wright, M. E., Shadomy, S. V., Bradley, J. S., Morrow, M. G., Pavia, M. G., Bower, W. A. (2014). Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults [Internet]. Emerging Infectious Diseases, 20(2). Retrieved May 1, 2014, from http://dx.doi.org/10.3201/eid2002 .130687
23. Inglesby, T. V., Dennis, D. T., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Tonat, K. (2000). Plague as a biological weapon: Medical and public health management. Working Group on Civilian Biodefense. The Journal of the American Medical Association, 283(17), 2281-2290.
24. Inglesby, T. V., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Friedlander, A. M., Tonat, K. (1999). Anthrax as a biological weapon: Medical and public health management. Working Group on Civilian Biodefense. The Journal of the American Medical Association, 281(18), 1735-1745.
25. Inglesby, T. V., O'Toole, T., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Tonat, K. (2002). Anthrax as a biological weapon, 2002: Updated recommendations for management. The Journal of the American Medical Association, 287(17), 2236-2252.
26. Khan, A. S., Morse, S., & Lillibridge, S. (2000). Publichealth preparedness for biological terrorism in the USA. Lancet, 356(9236), 1179-1182.
27. Khan, A., & Richter, A. (2012). Dispensing mass prophylaxis-the search for the perfect solution. Homeland Security Affairs, 8(3), 1-3.
28. Klietmann, W. F., & Ruoff, K. L. (2001). Bioterrorism: Implications for the clinical microbiologist. Clinical Microbiology Reviews, 14(2), 364-381.
29. Kman, N. E., & Nelson, R. N. (2008). Infectious agents of bioterrorism: A review for emergency physicians. Emergency Medicine Clinics of North America, 26(2), 517-547, x-xi.
30. Koirala, J. (2006). Plague: Disease, management, and recognition of act of terrorism. Infectious Disease Clinics of North America, 20(2), 273-287, viii.
31. Kyriacou, D. N., Adamski, A., & Khardori, N. (2006). Anthrax: From antiquity and obscurity to a front-runner in bioterrorism. Infectious Disease Clinics of North America, 20(2), 227-251, viii.
32. Lee, J. J., Johnson, S. J., & Sohmer, M. J. (2009). Guide for mass prophylaxis of hospital employees in preparation for a bioterrorist attack. American Journal of Health System Pharmacy, 66(6), 570-575.
33. Nafziger, S. D. (2005). Smallpox. Critical Care Clinics, 21(4), 739-746, vii.
34. Osterbauer, P. J., & Dobbs, M. R. (2005). Neurobiological weapons. Neurologic Clinics, 23(2), 599-621.
35. Pile, J. C., Malone, J. D., Eitzen, E. M., & Friedlander, A. M. (1998). Anthrax as a potential biological warfare agent. Archives of Internal Medicine, 158(5), 429-434.
36. Recommendations of the CDC Strategic Planning Workgroup. (2000). Biological and chemical terrorism: Strategic plan for preparedness and response. Morbidity and Mortality Weekly Report: Recommendations and Reports, 49(RR-4), 1-14.
37. Rotz, L. D., Khan, A. S., Lillibridge, S. R., Ostroff, S. M., & Hughes, J. M. (2002). Public health assessment of potential biological terrorism agents. Emerging Infectious Diseases, 8(2), 225-230.
38. Saks, M. A., & Karras, D. (2006). Emergency medicine and the public's health: Emerging infectious diseases. Emergency Medicine Clinics of North America, 24(4), 1019-1033.
39. Shapiro, R. L., Hatheway, C., Becher, J., & Swerdlow, D. L. (1997). Botulism surveillance and emergency response. A public health strategy for a global challenge. The Journal of the American Medical Association, 278(5), 433-435.
40. Simon, J. D. (1997). Biological terrorism. Preparing to meet the threat. The Journal of the American Medical Association, 278(5), 428-430.
41. Torok, T. J., Tauxe, R. V., Wise, R. P., Livengood, J. R., Sokolow, R., Mauvais, S., Foster, L. R. (1997). A large community outbreak of salmonellosis caused by intentional contamination of restaurant salad bars. The Journal of the American Medical Association, 278(5), 389-395.
42. Turnbull, P. C. (1991). Anthrax vaccines: Past, present and future. Vaccine, 9(8), 533-539.
43. Villar, R. G., Elliott, S. P., & Davenport, K. M. (2006). Botulism: The many faces of botulinum toxin and its potential for bioterrorism. Infectious Disease Clinics of North America, 20(2), 313-327, ix.
44. Wright, J. G., Quinn, C. P., Shadomy, S., & Messonnier, N. (2010). Use of anthrax vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. Morbidity and Mortality Weekly Report: Recommendations and Reports, 59(RR-6), 1-30.
45. Zilinskas, R. A. (1997). Iraq's biological weapons. The past as future? The Journal of the American Medical Association, 278(5), 418-424.